Signaling pathway networks mined from human pituitary adenoma proteomics data
© Zhan and Desiderio; licensee BioMed Central Ltd. 2010
Received: 9 March 2009
Accepted: 28 April 2010
Published: 28 April 2010
We obtained a series of pituitary adenoma proteomic expression data, including protein-mapping data (111 proteins), comparative proteomic data (56 differentially expressed proteins), and nitroproteomic data (17 nitroproteins). There is a pressing need to clarify the significant signaling pathway networks that derive from those proteins in order to clarify and to better understand the molecular basis of pituitary adenoma pathogenesis and to discover biomarkers. Here, we describe the significant signaling pathway networks that were mined from human pituitary adenoma proteomic data with the Ingenuity pathway analysis system.
The Ingenuity pathway analysis system was used to analyze signal pathway networks and canonical pathways from protein-mapping data, comparative proteomic data, adenoma nitroproteomic data, and control nitroproteomic data. A Fisher's exact test was used to test the statistical significance with a significance level of 0.05. Statistical significant results were rationalized within the pituitary adenoma biological system with literature-based bioinformatics analyses.
For the protein-mapping data, the top pathway networks were related to cancer, cell death, and lipid metabolism; the top canonical toxicity pathways included acute-phase response, oxidative-stress response, oxidative stress, and cell-cycle G2/M transition regulation. For the comparative proteomic data, top pathway networks were related to cancer, endocrine system development and function, and lipid metabolism; the top canonical toxicity pathways included mitochondrial dysfunction, oxidative phosphorylation, oxidative-stress response, and ERK/MAPK signaling. The nitroproteomic data from a pituitary adenoma were related to cancer, cell death, lipid metabolism, and reproductive system disease, and the top canonical toxicity pathways mainly related to p38 MAPK signaling and cell-cycle G2/M transition regulation. Nitroproteins from a pituitary control related to gene expression and cellular development, and no canonical toxicity pathways were identified.
This pathway network analysis demonstrated that mitochondrial dysfunction, oxidative stress, cell-cycle dysregulation, and the MAPK-signaling abnormality are significantly associated with a pituitary adenoma. These pathway-network data provide new insights into the molecular mechanisms of human pituitary adenoma pathogenesis, and new clues for an in-depth investigation of pituitary adenoma and biomarker discovery.
Our long-term goals for this human pituitary study are to clarify the molecular mechanisms that are involved in pituitary adenoma pathogenesis and to discover tumor biomarkers. Towards those ends, a series of pituitary adenoma proteomic expression data, which include 111 proteins identified from a human pituitary non-functional adenoma tissue , 56 differentially expressed proteins (DEP's) from human pituitary nonfunctional adenoma tissues and from prolactinoma tissues [2, 3], nine nitroproteins and three nitroprotein-protein complexes from a human pituitary nonfunctional adenoma tissue , and eight nitroproteins from a pituitary control tissue [5, 6], were analyzed. There is a pressing need to clarify the significant signaling pathway networks that involve those pituitary adenoma proteins, DEP's, and nitroproteins in order to clarify and to better understand - on a molecular level - pituitary adenoma pathogenesis. Knowledge of significant signaling pathway networks will provide important clues and clear directions for an in-depth investigation of pituitary adenomas, for the discovery of tumor biomarkers, and for the development of efficacious therapeutic agents.
Over the past decades, high-throughput "-omic" technologies (genomics, transcriptomics, and proteomics) have been used in many fields, including biology and human diseases. Relative to the traditional molecular biology methods that had been used to study the role of a single gene, single protein, or single small-molecule model, those "-omic" data have driven the rapid development of systems biology to study a multiple-factor model of disease and to address the network of interaction and regulatory events that contribute to a disease. Pathway biology, as one important component of systems biology, has been extensively developed. Omic data-based pathway biology relies on an accurate and effective pathway analysis system. The Ingenuity Pathway Analysis (IPA) system is an extensively used (>1,300 peer-reviewed publications citing IPA; February 13, 2009) pathway analysis system that includes a large-scale knowledge base (~2.2 million scientific findings and 235 canonical pathways; February 13, 2009). IPA can identify statistically significant signaling pathway networks by analyzing the -omic data in those numerous canonical-pathway databases.
Proteomic data obtained from pituitary adenoma tissues [1–6] were analyzed with IPA software to define which well-characterized cell-signaling and metabolic pathways could be the most relevant during pituitary adenoma pathogenesis. This present study used the IPA system to reveal the significant signaling pathway networks that involve pituitary adenoma proteins, DEP's, and nitroproteins in an attempt to better understand the molecular mechanisms that are involved in pituitary adenoma pathogenesis, to discover potential biomarkers, and to develop efficacious therapeutic agents.
Pathway networks derived from protein-mapping data
Among the 154 identifiers that represented the 111 proteins that were identified from human pituitary adenoma tissue, 147 identifiers were mapped to the corresponding molecules (genes; proteins), except for 7 identifiers (Additional file 1, Table S1). A total of 106 identifiers were eligible to proceed into pathway analysis after 41 duplicate identifiers were removed from those 147 mapped identifiers. Each identifier was annotated with a Swiss-Prot accession number, gene name, protein name, subcellular location, biofunction, and potential targets of drugs (Additional file 1, Table S1).
Signaling Pathway Networks that Involve Pituitary Adenoma Mapping Proteins.
Nodes (genes; proteins) in Network
Identified Nodes (Proteins)
AKR1B1, ANXA1, ANXA2, ANXA5, APCS, C3, CAT, Complement component 1, ECHS1, ENO1, ERK, F10, FGG, FTH1, FTL, FYN, GDI2, GH1, Glutathione transferase, GST, GSTM2, GSTO1, GSTP1, HADHB, Nfat, PCBP1 (includes EG:5093), PHB (includes EG:5245), PLC, PPIA, PRDX2, PRDX6, SERPINE1, Stat3-Stat3, T3-TR-RXR, UCHL1
Cancer, Cell-To-Cell Signaling and Interaction, Small Molecule-Biochemistry
ADCY, ATP5B, CALR, CAPNS1, CCNH, CRABP2, ERP29, FHL2, FKBP5, G-protein beta, GNAO1, GNB2, GNB3, HLA-A, HSF1, HSP, Hsp27, Hsp70, Hsp90, HSPA5, HSPA8, HSPB1, KRT19, MHC Class I, NFkB, NME2, P4HB, PAFAH1B2, PDIA3, Rbp, RBP1, SOD1, Tap, YWHAE, YWHAQ (includes EG:10971)
Post-Translational Modification, Protein Folding, Hematological Disease
14-3-3, Actin, Akt, ALB, APOA1, Calmodulin, Calpain, CBS, Dynamin, E2f, F Actin, GSN, HNRNPC, HPX, IMMT, Integrin, KRT9, LDL, MAP3K8, Mapk, NAPA, PI3K, PITPNA, Pkc(s), Pld, Proteasome, PSMC1, PSME1, PSME2, Ras, TF, Tgf beta, TPM3, TPM4, Tropomyosin
Organ Morphology, Reproductive System Development and Function, Molecular Transport
A1BG, ADSL, ARHGEF5, BLVRB, C22ORF28, C4ORF27, CREBL2, Cytochrome c, EIF6, ENO2, ERBB2, FGF7, FSH, HNF4A, IDH1, IDH3A, IL6, KLHDC3, LEP, MCCC1, MYL6, MYL9 (includes EG:10398), NDUFS3, NPNT, OFD1, PPARGC1A, RIOK1, SLC25A20, STK17A, SUCLA2, THSD1, TIMD2, TLN1, VAT1, YWHAB
Lipid Metabolism, Molecular Transport, Small-Molecule Biochemistry
ACTR3, AKR7A2, BMP3, Ck2, DUSP8, EBAG9, EEF1A1, ELP3, ERAF, Histone h3, HSD17B10, Insulin, Jnk, KITLG (includes EG:4254), KLK11, MAGED2, MAS1, MDH2, OVOL1, P38 MAPK, PDGF BB, PGLS, PPM1L, PRKRIR, RNA polymerase II, SF3B2, SLC25A11, SLC25A12, STARD10, STK4, TGFB1, UGDH, VAPB, WASF3, WDR1
Cell Death, Hematological Disease, Cellular Development
3-hydroxybutyric acid, ABCC9, AK1, ANXA4, AQP9, BPGM, CA14, CA1 (includes EG:759), CCT3, EEF1G, EIF4EBP2, FADS2, FBXO8, FH, GNPAT, HNF1A, ILF2 (includes EG:3608), INS1, KCNJ8, KCNJ11, L-triiodothyronine, LDHB, MGST3, MYC, PAX4, PGAM1, PRDX3, SCD2, SLC37A4, SRI, SRM, TPI1, UMPS, VDAC2, XRCC6
Lipid Metabolism, Small-Molecule Biochemistry, Carbohydrate Metabolism
Network 1 functions in cancer, cell-to-cell signaling and interaction, and small-molecule biochemistry (Figure 1A), and includes 35 nodes (genes; proteins); 27 of the proteins (77% of the total nodes) were identified with mass spectrometry (MS). GH1 and ERK play key roles in Network 1.
Network 2 functions in post-translational modifications, protein-folding, and hematological disease (Figure 1B), and includes 34 nodes (genes; proteins); 25 of the proteins (74% of the total nodes) were identified with MS. NF-kB, HSPA, and G-protein play key roles in Network 2.
Network 3 functions in organ morphology, reproductive-system development and function, and molecular transport (Figure 1C), and include 35 nodes (genes; proteins); 17 proteins (49% of the total nodes) were identified with MS. MAPK, Pkc, Ras, PI3K, Akt, and Calmodulin play key roles in Network 3.
Network 4 functions in lipid metabolism, molecular transport, and small-molecule biochemistry (Figure 1D), and includes 35 nodes (genes; proteins); 13 proteins (37% of the total nodes) were identified with MS. HNF4A, ERBB2, and FSH play key roles in Network 4.
Network 5 functions in cell death, hematological disease, and cellular development (Figure 1E), and includes 36 nodes (genes; proteins); 11 proteins (31% of the total nodes) were identified with MS. TGFB1, Jnk, P38 MAPK, and insulin play key roles in Network 5.
Network 6 functions in lipid metabolism, small-molecule biochemistry, and carbohydrate metabolism (Figure 1F), and includes 35 nodes (genes; proteins); 11 proteins (31% of the total nodes) were identified with MS. INS1, MYC, and HNF1A play key roles in Network 6.
Figure 4 shows the scheme of a representative canonical pathway - the NRF2-mediated oxidative stress response. The extracellular oxidative stress-related factors induce intracellular electophile ROS formation to activate the NRF2 via MAPK-signaling pathways such as the Ras/Raf-ERK, JNK, p38MAPK, and PI3K/AKT pathways. The activated NRF2 is translocated into the nucleus to initiate antioxidative gene/protein expression such as antioxidant proteins (SOD, GPX2, CAT, FTH1, FTL, etc.) to reduce oxidative damage, chaperone/stress-response proteins, and ubiquitination and proteasonal degradation proteins to repair and remove damaged proteins. Also, NRF2 involves the regulation of expression of detoxifying proteins for cell survival. However, the dysregulation of this NFR2 pathway will cause the formation of more reactive metabolites, which in turn could promote tumorigenesis. Some components in this pathway have been identified with our proteomics study, and include FTL, FTH1, CAT, SOD, AFAR, FKBP5, and ERP29. The detailed components of the other canonical pathways that are derived from the pituitary adenoma protein-mapping data are shown in Additional file 2, Figures S1.1-S1.36.
Pathway networks derived from comparative proteomics data
Among the 86 identifiers that represent the 56 DEP's that were identified from human pituitary adenoma tissues, 75 identifiers were mapped to the corresponding molecules (genes; proteins) except for 11 identifiers (Additional file 1, Table S2). The 75 identifiers are significant because they derive from a comparison of adenomas and controls. A total of 47 identifiers were eligible to proceed into pathway analysis after 28 duplicate identifiers were removed from those 75 mapped identifiers. Each identifier was annotated with a Swiss-Prot accession number, gene name, fold-change, protein name, subcellular location, biofunction, and potential targets of drugs (Additional file 1, Table S2).
Signaling Pathway Networks that Involve Human Pituitary Adenoma Differentially Expressed Proteins (DEPs).
Nodes (genes; proteins) in Network
Identified Nodes (DEPs)
AKR1B1, Akt, ATP5B, CAPZB, Caspase, CRYM, Cytochrome c, DBI, ERK, F10, FYN, GDI1, GH1, GLO1, GPX4, GSTM2, HSP90B1, HSPB1, HSPB8, Igfbp, IGFBP6, Insulin, Jnk, P38 MAPK, PDGF BB, PI3K, Pka, PLC, PPID, PPP2R2A, PRL, Ras, TGM2, VIM, YWHAQ (includes EG:10971)
Cancer, Endocrine System Development and Function, Organ Morphology
ACOT2, ACSL1, ADRB3, AKR1B1, ANGPTL4, COL6A2, COX2, COX6B1, Cytochrome c oxidase, DBI, DLK1, DNAJB6, EDN2, ERP29, F2, GCLC, IDH1, IL4R, L-triiodothyronine, LIPE, MMP19, MYCL1, MYLPF, MYOD1, OGN, PPARG, PRDX3, prostaglandin E2, RXRB, SERPINB8, SKI, SLC2A1, TAGLN3, TGFB1, TNF
Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry
ALB, APOA1, CALB1, CD59, CNTF, CXCR4, CYP2E1, DDIT3, EPO, FGG, G alpha, GH2, GNAO1, GNAS, GPNMB, GPSM1, HBA2, HBB (includes EG:3043), HBD, Histone h3, IFNG, IGFBP2, IGLC1, KLF3, KRT16, Mapk, NFkB, NUPR1, PIK3R1, PIM3, SCGN, SH2B1, SOCS3, TAC1, TPH2
Hematological System Development and Function, Tissue Morphology, Hematological Disease
Network 7 functions in cancer, endocrine-system development and function, and organ morphology (Figure 5A) and includes 35 nodes (genes; proteins); among those 35 nodes, 22 DEPs (63% of the total nodes) were identified with MS. GH1, ERK, P38 MAPK, PRL, Insulin, Akt, Ras, and Jnk play key roles in Network 7.
Network 8 functions in lipid metabolism, molecular transport, and small-molecule biochemistry (Figure 5B), and include 35 nodes (genes; proteins); 11 DEP's (31% of the total nodes) were identified with MS. TGFB1, TNF, PPARG, and MYOD1 play key roles in Network 8.
Network 9 functions in tissue morphology, and hematological-system development, function, and disease (Figure 5C), and include 35 nodes (genes; proteins); 10 DEP's (29% of the total nodes) were identified with MS. MAPK, IFNG, NFkB, and EPO play key roles in Network 9.
Figure 8 shows, as an example, the complicated mitochondrial dysfunctional pathway. The mitochondrial dysfunctional pathway was distributed within five regions of a cell - cytoplasm, outer mitochondrial membrane, intermembrane space, inner mitochondrial membrane, and mitochondrial matrix. The mitochondrial complexes I - V locate in the inner mitochondrial membrane. Gene mutations that cause mitochondrial dysfunction include Complex I (NADH dehydrogenesase) (NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS6, NDUFS7, NDUFS8, ND1, ND4, ND5, NDUFA1, NDUFA8, NDUF13, NDUFAF1, and NDUFB9), Complex II (succinate dehydrogenase) (SDHA, SDHB, SDHC, and SDHD), Complex III (cytochrome bc 1) (UQCRB, CYTB), Complex IV (cytochrome c oxidase) [COX3 (cyclooxygenase 3)], and other genes (APP, amyloid β, presenin-1, and α-synuclein). Our comparative proteomics data demonstrate that some components of mitochondrial complexes are significantly up-regulated in pituitary adenomas relative to controls; for example, ATP5B (ATP synthase, H+-transporting, mitochondrial F1 complex, beta polypeptide; 5-fold), COX6B1 (cytochrome c oxidase subunit Vib polypeptide 1; 9-fold), and NDUFS8 (NADH dehydrogenase ubiquinone Fe-S protein 8; 5-fold). Moreover, GPX4 (glutathione peroxidase 4) was significantly down-regulated (26-fold) in pituitary adenomas relative to controls. GPX4 plays important roles in the cytochrome c - apoptosis pathway.
Figure 9 shows the ERK/MAPK signaling pathway. The extracellular signals are transducted into the cytoplasm via the receptor tyrosine kinase (RTK) and the integrin receptor to activate the Ras/Raf pathway. Ras is regulated by PKC and SOS that is regulated by Src and FYN signals. Raf includes three subfamilies A, B, and C. A-Raf is activated by the Ras signal. B-Raf is activated by Rap1, PKA, and 14-3-3 signals. C-Raf is activated by Ras, PKA, and 14-3-3 signals. ERK1/2 are activated by Rafs-MEK1/2 signals. The activated ERK1/2's will perform their biological roles in the cytoplasm such as phosphorylation of cytoskeletal proteins, ion channels and receptors, and regulation of apoptosis and translation; or will translocate into the nucleus to regulate the transcription of multiple genes such as Stat1/3, Myc, CREB, histone H3, etc. Compared to human pituitary controls, in pituitary adenomas, the FYN (FYN oncogene related to SRC, FGR, YES) was up-regulated (4-fold), 14-3-3 protein down-regulated (44-fold), HSPB1 (heat shock 27 kDa protein 1) down-regulated (5-fold), and PPP2R2A (protein phosphatase 2 regulatory subunit B alpha isoform) down-regulated (8-fold), within the ERK/MAPK signaling pathway system. Also, the PKA regulatory subunit type I beta was nitrated (Additional file 1, Table S3) to most probably interfere with PKA functions; that nitration suggests that oxidative/nitrative stress signals are also involved in the regulation of the ERK/MAPK signaling system. The detailed components of the other canonical pathways that are derived from pituitary adenoma comparative proteomic data are shown in the Additional file 2, Figures S2.1-S2.7.
Pathway networks derived from nitroproteomic data
A total of 12 identifiers that represent nine nitroproteins, and three non-nitrated proteins, from a human pituitary adenoma tissue were mapped to their corresponding genes/proteins (Additional file 1, Table S3). A total of 10 identifiers were eligible to proceed into pathway analysis, except for LILRA4 and ZNF432. Each identifier was annotated with a Swiss-Prot accession number, gene name, nitration status, protein name, subcellular location, biofunction, and potential targets of drugs (Additional file 1, Table S3). Twelve identifiers that represent nine nitroproteins from human pituitary control tissue were also mapped to nine genes. Nine network-eligible identifiers proceeded to pathway analysis (Additional file 1, Table S4). Nitration usually decreases the activity of a protein.
Signaling Pathway Networks that Involve Nitroproteomic Data From Pituitary Adenoma and Control.
Nodes (genes; proteins) in Network
Identified Nodes (Nitroproteins)
ARHGAP5, beta-estradiol, FAM105B, GNL1, GRIP2, H2-Q4, Histone h3, IFI203, IL17B, IL17C, IL1B, IL1F5, IL1F6, IRAK2, IRG1, MAPK11 PREDICTED, MHC CLASS I D2D ANTIGEN, MMD, NFRKB, PCDH7, Pka, PLD3, PRKAR1B, PSMA2, RAB32, RHOA, RHPN2, SCUBE2, TM4SF1, TNF, TPD52L2, TWIST2, UBB, UBC, ZNF267
Cancer, Cell Cycle, Reproductive System Disease
ACTA2 (includes EG:59), ACTC1, ACTG2, Actin, BCL2, beta-estradiol, BMF, CAP2, ELK1, EPS8L2, ESPN, F Actin, FCAR, FEZ2, FOS, GAK, GZMC, KLK11, KRT81 (includes EG:3887), LIMA1, MBOAT5, MSMB, PAQR3, PDZK1IP1, PRKG2, PRPS1, PSMA2, PTPRK, RAB31, RPN2, SELENBP1, SNAP91, STC1, TGFB1, TMOD3
Gene Expression, Cellular Development, Connective Tissue Development and Function
Figure 13 shows the representative p38 MAPK signaling pathway. The extracellular inflammatory cytokine signals (such as TNF, TGF-β, and IL-1) are transducted into the cytoplasm via a binding to their corresponding receptors in the membrane to activate ASK1 and TAK1. p38 MAPK's include four subfamilies (α, β, γ, δ) that are activated by ASK1/MKK4, TAK1/MKK3/6, and MKP1/5 signals. The activated p38 MAPKs are translocated into the nucleus to activate the transcription of multiple genes such as CREB, c-Myc, Stat1, histone H3, Elk-1, etc., and to regulate apoptosis. Our pituitary adenoma nitroproteomic study has discovered the IL1-IL1R-IRAK2 complex in a human pituitary adenoma tissue; IL-1 was nitrated, and IRAK2 (interleukin-1 receptor-interacting protein 2) was identified to associate with IL1R.
Additional file 2, Figure S3.4 shows the cell-cycle G2/M DNA damage checkpoint-regulation pathway. p53 and cdc25 B/C play important roles in this oxidative damage-induced pathway. The 14-3-3 proteins (down-regulated 44-fold in pituitary adenomas compared to controls; Additional file 1, Table S2) are the important regulators in this pathway - they couple with Cdc25 B/C to participate in the nuclear export of Cdc25, and couple with Cdc2 and Cyclin B to participate in the cytoplasmic sequestration of cdc2 and cyclin B. The detailed components of the other canonical pathways that are derived from the pituitary adenoma nitroproteomic data are shown in Additional file 2, Figures S3.1-S3.10.
The present study, for the first time, used bioinformatics pathway analysis to reveal the significant signaling pathways and networks that are associated with pituitary adenomas; three types of proteomic data were used - pituitary adenoma protein-mapping , comparative proteomic [2, 3], and nitroproteomic [4–6]. Protein-mapping data were obtained with a 2DGE-arrayed pituitary adenoma proteome, followed by MS characterization of the proteins. The protein-mapping data-derived pathways and networks could reflect each potential pathway network that exists in a human pituitary adenoma proteome, and that associates with its pathophysiology. Those pathway networks are the baseline for the discovery of adenoma-related pathway networks. Comparative proteomic data were obtained from 2DGE-arrayed adenoma and control proteome images, followed by MS characterization of DEP's. Those DEP data-derived pathway networks will reflect significant adenoma-related pathway networks. Nitroproteomic data include those endogenous proteins that were nitrated at a tyrosine residue. Tyrosine nitration, a chemically stable marker of oxidative stress, alters protein function, and is extensively associated with tumor inflammation and neurodegenerative disease. The nitroproteomic data-derived pathway networks will directly reflect the pathways of oxidative damage that contribute to the formation of a pituitary adenoma. Among the complicated pathway networks described above, several signaling pathways and networks were found to be significantly associated with a pituitary adenoma, and include mitochondria dysfunction, oxidative stress, cell-cycle dysregulation, and the MAPK-signaling system. Those four systems will be described below.
Mitochondria are dynamic intracellular organelles that are essential for cellular life, death, and differentiation, and play a central role in oxidative metabolism and apoptosis. Mitochondrial dysfunctions underlie a broad spectrum of human diseases [7, 8] that include cancer [9, 10], neurodegenerative diseases , cardiovascular diseases , diabetes mellitus , and inflammatory diseases [14, 15]. Notable differences in the structure and function of mitochondria appear between cancer and normal cells, and include differences in mtDNA sequence, molecular composition, and metabolic activity [9, 10]. Mitochondria involve multiple metabolic functions that include oxidative phosphorylation - an energy-generating process that couples the oxidation of respiratory substances to the synthesis of ATP, oxidative decarboxylation of pyruvate, the tricarboxylic acid cycle, fatty-acid oxidation, glycolysis, intracellular homeostasis of inorganic ions such as calcium and phosphate, and intracellular apoptosis . Mitochondrial dysfunction in cancer includes an increased gluconeogenesis, reduced pyruvate oxidation and increased lactic acid production, increased glutaminolytic activity, and reduced fatty-acid oxidation. The activity of certain mitochondrial enzymes that are integral to the process of oxidative phosphorylation is decreased in cancer compared to normal cells; those enzymes include ATPase, cytochrome c oxidase, and adenine nucleotide translocase. The additional alterations of gene expression between cancer and normal cells include the anti-apoptotic oncogenes that encode Bcl-2 and Bcl-XL, and genes that encode the peripheral benzodiazepin receptor (PBR), the PBR-associated protein Prax-1, and mitochondrial creatine kinase. The expression of BAX, a pro-apoptotic, inner mitochondrial membrane protein, is also reduced in some cancer cell-lines. The metabolic imbalances and the enhanced resistance to mitochondrial apoptosis are the prominent features of cancer cells, and tumors rely heavily on glycolysis to meet their metabolic demands . Mitochondrial dysfunctions have been proposed as a cause of cancer, and the citrate inhibition of glycosis has been proposed as a cancer treatment . Mitochondria play crucial roles in this cancer-cell biology. Mitochrondrial dysfunction is a biomarker for the early detection of cancer, and is a therapeutic target for cancer.
Pituitary adenoma protein-mapping data clearly reveal the mitochondria-related signaling pathways that include fatty-acid elongation in mitochondria, glycolysis/gluconeogenesis, and oxidative stress that function in human pituitary adenoma cells (Figures 2 and 3). The DEP data also clearly reveal the significant signaling pathways that include mitochondrial dysfunction, oxidative phosphorylation, and oxidative-stress response in a human pituitary adenoma (Figures 6 and 7). Figure 8 shows the canonical pathway of mitochondrial dysfunctions.
Mitochondrial dysfunction could be confirmed with a mitochondrial morphological change in a human pituitary tumor. Studies found an increased number of mitochondria, and ultrastructurally abnormal mitochondria were present in pituitary oncocytomas . Large mitochondria and mitochondrial swelling were present in a pituitary adenoma with hyperprolactinemia; those findings could be attributable to the prolonged intake of steroids and/or ischemia . Characteristic vesicular mitochondria are present in adrenocortical-pituitary hybrid tumor cells that cause Cushing's syndrome . Moreover, melatonin as an apoptotic inducer of tumor cells significantly inhibited prolactinoma cell proliferation, increased prolactinoma cell apoptosis, induced mRNA expression of Bax and cytochrome c protein expression, and, conversely, inhibited the mRNA expression of Bcl-2 and the mitochondrial membrane potential. Those data suggest that melatonin inhibits proliferation and induces apoptosis of a rat pituitary prolactin-secreting tumor via a perturbation of mitochondria physiology . The ultrastructure of cells shows giant mitochondria and an increased number of mitochondria comparable to oncocytic adenomas in human pituitary adenomas that secrete growth hormone and prolactin, and electron microscopy shows many, in part densely arranged, mitochondria in human non-functioning pituitary adenomas . Anti-mitochondrial staining shows intense and granular mitochondria, and electron microscopy shows swollen mitochondria in the cytoplasm with featured lamellar cristae in the spindle-cell oncocytoma of the adenohypophysis .
Evidence demonstrates that dysfunctional mitochondria, not oxygen insufficiency, cause cancer cells to produce inordinate amounts of lactic acid that impact on the treatment of cancer . Studies demonstrate that cancer-cell mitochondria are pro-apoptotic targets for the marine antitumor drug lamellarin D . Mitochondria are emerging as biomarkers for the early detection of, and for novel therapeutic targets in, cancer [17, 26–29]. Therefore, mitochondrial dysfunction is not only a significant signal in a human pituitary adenoma, but also provides biomarkers for early detection, and targets for novel therapeutic agents to treat a pituitary adenoma.
Oxidative stress is produced when the balance is disturbed between an upload of free radical/reactive oxygen/nitrogen species (ROS/RNS) from in vivo formation and from in vitro environmental carcinogens, and the capability of endogenous antioxidant defense mechanisms to remove those reactive species [30, 31]. Oxidative stress can cause injury to several important cellular components such as proteins, DNA, and membrane lipids. An increased formation of ROS/RNS can promote the development of tumorigenesis, and the 'normal' rates of ROS/RNS generation might account for the increased risk of cancer development . The mitochondrial oxidative respiratory chain and the oxidative phosphorylation system are the central components that produce endogenous ROS such as superoxide radicals (O2.-). In a pathogenesis, large amounts of nitric oxide (NO), the most important RNS component, are generated from the inducible nitric oxide synthase (iNOS) system. The superoxide radicals can rapidly react with nitric oxide to produce the more toxic peroxynitrite anion (ONOO-), or the highly reactive hydroxyl radical (OH.), to attack proteins, DNA, and membrane lipids. Many studies have indicated the presence of NOS in the human and rat pituitary [33–37], and the increased activities of NOS and its mRNA have been found in pituitary adenomas relative to controls [37, 38]. NO is involved in the hypothalamic-pituitary-adrenocortical axis . NO plays an important role to activate the release of luteinizing hormone-releasing hormone (LHRH) and follicle-stimulating hormone-releasing hormone (FSHRH) from the hypothalamus, and of LH and FSH from the pituitary [40–42]; to stimulate or inhibit the secretion of PRL ; to regulate the secretion of growth hormone (GH) in the normal human pituitary and in acromegaly [44, 45]; and to modulate GH secretion in a dose-dependent manner in GH adenomatous cells from human pituitary adenomas .
Our nitroproteomics study  discovered nine tyrosine-nitrated proteins in human pituitary adenoma tissues, and that each tyrosine nitration site is located within an important protein domain to alter protein functions. However, with the formation of ROS and RNS, the in vivo antioxidative mechanism is also initiated against ROS/RNS . The anti-oxidative system includes enzymatic [superoxide dismutase (CuZnSOD, MnSOD), catalase, glutathione peroxidase] and non-enzymatic [Vitamin C, Vitamin E, carotenoids, thiol antioxidants (glutathione, thioredoxin, and lipoic acid), flavonoids, selenium, and others] antioxidants, as well as the antioxidant interactions with various regulatory factors such as NF-κB, AP-1, and Nrf2 . Copper- and zinc-containing superoxide dismutase (CuZnSOD) in most parts of cells and manganese-containing superoxide dismutase (MnSOD) in the mitochondrial matrix can effectively scavenge the superoxide radicals to generate H2O2 [48–50], which is removed by peroxiredoxins (thioredoxin-dependent peroxidase enzymes) and GPX's (glutathione peroxidases) [51, 52]. The decrease or deficiency of the activities of those antioxidative enzymes could contribute to tumorigenesis [52, 53]. Studies show that the content of CuZnMOD is markedly higher in normal cells than in pituitary adenoma cells . Pivotal to the antioxidant response is the transcription factor Nrf2 (nuclear factor-E2-related factor-2) that is mainly located in the cytoplasm under basal conditions . Under oxidative stress derived from the accumulation of ROS [56, 57] and RNS [58, 59], Nrf2 can quickly translocate into the nucleus and elicit an antioxidant response. Nrf2 signaling is regulated by multiple components [55, 60]. At least four components in combination [Nrf2, Keap1 (Kelch-like ECH-associated protein 1), a group of small musculoaponeurotic fibrosarcoma (Maf) proteins, and a cis-acting enhancer called antioxidant response element (ARE) or electrophile responsive element (EpRE)] are essential for the antioxidant response. The Nrf2 signaling pathway not only regulates the expression of antioxidative genes, but also regulates the anti-inflammatory response, the molecular chaperone/stress-response system, and the ubiquitin/proteasome system . Any decrease in the capability of this antioxidant protective system could increase the susceptibility to oxidative stress, tumor inflammation, carcinogen toxicity, and tumorigenesis.
Our pathway analysis of pituitary adenoma protein-mapping data and DEP's has clearly revealed the oxidative stress and Nrf2-mediated oxidative stress-response pathway (Figures 2, 3, 6, and 7) in pituitary adenomas. Figure 4 presents the canonical pathway of the Nrf2-mediated oxidative-stress response. Therefore, the oxidative stress-antioxidative stress-response system is not only a significant signaling pathway of pituitary adenoma formation, but also those components in this pathway could be the novel targets to develop effective therapeutic agents that could be used for human pituitary adenomas [61, 62].
The basic biological characteristics of tumor cells are the unrestricted proliferation and growth compared to normal cells; the latter are in a state of balance between restricted proliferation and apoptosis. This proliferation process is controlled by the cell cycle. The cell cycle includes four phases (G0) G1 → S → G2 → M → G1 (G0) that will make the cell grow, replicate their genome, and divide; this cycle is regulated by a cyclically operating biochemical system that includes cyclins, cyclin-dependent kinases (CDK), and their inhibitors (CDKI) . The CDKI families mainly include the INK family (INK4a/p16, INK4b/p15, INK4c/p18, and INK4d/p19) and the WAF/KIP family (WAF1/p21, KIP1/p27, and KIP2/p57). The progression through a cell cycle is mainly regulated by the fluctuations in the concentration of cyclins and CDKI that is achieved through the programmed degradation of these proteins by the proteolysis within the ubiquitin-proteasome system . Cyclin D1 is expressed at the G0/G1 transition, and is involved in the regulation of progression through G1 into the S phase. Cyclin E expression occurs at the beginning of G1, maximizes at the G1/S transition, is degraded at the beginning of the S phase, and is involved in DNA replication. Cyclins D and E, in combination with CDKs/CDKI, regulate the G1 and S phases to prepare for cell division. Cyclin A accumulates in late G1, maximizes during the S phase, and is degraded in the M phase. Cylin B is necessary for the transition from G2 to mitosis. Studies have demonstrated that the ectopic expression of cyclin D and the overexpresion of Cyclins A, B, and E occur in a pituitary adenoma to regulate different phases of the cell cycle, and to accelerate the progression of the cell-cycle . The overexpressed pituitary tumor-transforming gene (PTTG), as an early change in pituitary tumorigenesis, is also dependent on the cell cycle; PTTG expression is low at the G1/S border, gradually increases during the S phase, peaks at the G2/M, and is attenuated as the cells enter G1 . The details on cell-cycle dysregulation in a human pituitary adenoma have been reviewed [64, 66–68].
The pathway analysis of our pituitary adenoma nitroproteomic data clearly revealed the cell-cycle G2/M DNA damage checkpoint-regulation pathway in human pituitary adenomas (Figure 11). Additional file 2, Figure S3.4 shows the canonical pathway of the cell-cycle G2/M DNA damage checkpoint regulation. DEP data clearly demonstrate that the important cell-cycle regulator 14-3-3 protein was down-regulated (44-fold) in pituitary adenomas compared to controls (Additional file 1, Table S2). Moreover, our nitroproteomic data demonstrate that a nitrated proteasome could interfere with the functions of the ubiquitin-proteasome system in the regulation of the cell cycle. Thus, oxidative/nitrative stress is also involved in the cell-cycle dyregulation in human pituitary adenomas. Furthermore, those components that regulate the cell cycle could be the novel targets for the development of an effective pituitary adenoma therapy; for example, the proteasome inhibitors can induce apoptosis in growth hormone-and prolactin-secreting rat pituitary tumor cells through a blocking of the cell cycle at the G2/M transition .
MAPK signaling abnormality
Mitogen-activated protein kinase (MAPK) signaling pathways play prominent roles in the between- and within-cell communications in normal cells and cancer cells . Those pathways link the extracelluar signals (stimuli such as growth hormone, growth factor, mitogens, cytokines, stress, etc.) to the functional cellular processes such as growth, profliferation, migration, and apoptosis. The basic MAPK pathway is stimulus (mitogens, growth factors, cytokines, stress, etc.) → G-protein (Ras, Rac, Cdc42, Rho) → MAPKKK (Raf, Tpl2, MEKK, MLK, TAK, ASK, TAO) → MAPKK (MEK) → MAPK (ERK, JNK, P38) to generate responses (proliferation, differentiation, apoptosis, and migration). ERKs (extracellular signal-regulated kinases), JNKs (c-Jun N-terminal kinases), and p38-MAPKs are the three main subfamilies of MAPKs. ERK 1/2 are activated by MEK1/2, which are activated by Raf, Ras, and growth factors or mitogens; Raf activity, as the main effector of Ras, is suppressed by cyclic AMP-dependent kinase (PKA) in a normal cell . JNKs are activated by MEK4/7, and p38-MAPKs are activated by MEK3/4/6. The upstream signal of MEK3/4/6/7 is from Rac, Rho, cdc42, cytokines, or stresses. ERKs function in the control of cell division. JNKs are critical regulators of transcription, and have the ability to promote apoptosis; however, the activation of nuclear factor kappa B (NF-κB) signaling can lead to the suppression of apoptosis. JNK and NF-κB signaling often play opposing roles in cancer. The activation of NF-κB is required to suppress JNK-activated apoptosis during tumorigenesis [72, 73]. The p38-MAPKs are strongly activated by inflammatory cytokines and environmental stresses, and p38 is required for the expression of TNFα and interleukin-1 during tumor inflammatory responses. p38 can function as a tumor suppressor; a decrease of p38 activity significantly contributes to tumorigenesis . Recent findings show that the cancerous mutations in MAPK pathways frequently affect Ras and B-raf. Ras/Raf mutation-activated pathways are important for cell survival and proliferation, whereas stress-activated pathways such as JNK and p38 largely seem to counteract malignant transformation. The balance and integration among those signal pathways could significantly contribute to tumorigenesis and to any response to drug therapy. The details of MAPK signaling pathways in cancer are reviewed [70, 75, 76]. The MAPK pathways are emerging as potential therapeutic targets for cancer [77, 78], and the development of inhibitors of MAPK pathways has a growing importance in cancer therapy.
The pathway analyses of our pituitary adenoma proteomic data clearly demonstrate that MAPK signaling pathways are involved in pituitary tumorigenesis. The protein-mapping data of pituitary adenomas show that ERK (Figure 1A), NFkB and F-protein (Figure 1B), MAPK, Ras, PKC and PI3K (Figure 1C), and JNK and p38-MAPK (Figure 1E) are the key nodes in their pathway networks. The comparative proteomic data show that Ras, ERK, JNK, p38-MAPK and Akt (Figure 5A), TNF and TGFb1 (Figure 5B), and MAPK and NFkB (Figure 5C) are the key nodes in their pathway networks; and that ERK/MAPK signaling (Figure 6) is the significant canonical pathway in adenomas.
The nitroproteomic data of human pituitary adenomas show that TNF and IL1B (Figure 10A) are the key nodes in their pathway networks; and that p38-MAPK signaling (Figure 11) is the significant canonical pathway that participates in an oxidative-stress response in an adenoma. The nitroproteomic data of human pituitary controls show that TGFb1 (Figure 10B) is the key node in its pathway network. Moreover, the PKA type I beta regulatory subunit is nitrated in human pituitary adenomas (Figure 10A; Additional file 1, Table S3), and that tyrosine nitration occurs within the dimerization region ; those nitrations could interfere with dimerization and affect PKA activity to suppress Raf activity. Figure 9 shows the canonical pathway of ERK/MAPK signaling, and Figure 13 the canonical pathway of p38 MAPK signaling. Studies have demonstrated the altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas , Gsα and Giα mutations in clinically nonfunctioning pituitary adenomas , and an H-ras mutation in a single aggressive prolactinoma or metastases from pituitary carcinomas . Recent studies demonstrate that an overexpression of B-Raf mRNA and protein is a feature of nonfunctional pituitary adenomas; that overactivity highlights an overactivity of the Ras-B-Raf-MAP kinase pathway to promote pituitary tumorigenesis , and that the low levels of Raf kinase inhibitory protein (RKIP) in a GH-pituitary adenoma correlate with poor clinical response to somatostatin analog therapy because RKIP can bind to and inhibit Raf1 kinase to attenuate MAPK signaling . The antiproliferative effect of somatostatin analogs involves the upregulation of p27 and downregulation of the MAPK pathway in human somatotrophinomas . Furthermore, studies demonstrate that dopamine induces an anti-proliferative effect and cell death via the dopamine D2 receptors, by means of the p38 MAPK and ERK pathways that involve oxidative stress, in pituitary tumor cells . Those data confirm that ERK-MAPK and p38-MAPK signaling pathways significantly function in human pituitary adenomas.
Strength and limitation
The strength of this study is (i) that, towards our long-term goals to clarify the molecular mechanism that are involved in pituitary adenoma pathogenesis and to discover tumor biomarkers, a series of human pituitary proteomic expression data (protein-mapping data, comparative proteomic data, and nitroprotemic data) were established; four important significant signal pathway networks that were derived from those proteomic expression data were discovered, including mitochondrial dysfunction, oxidative stress, cell-cycle dysregulation, and the MAPK signaling system; knowledge of those signal pathway networks will provide important clues and clear directions for our next step, an in-depth investigation of pituitary adenomas, for the discovery of tumor biomarkers, and for the development of efficacious therapeutic targets and drugs; (ii) that all protein data were confirmed with a "gold standard" tandem mass spectrometry-based amino acid sequence; and comparative proteomic data were confirmed with comparative transcriptomic data [2, 3]; (iii) that signal pathway networks derived from protein-mapping data provide the baseline data; comparative proteomic data that are involved in pathway networks reveal the protein expression change in the pathway networks to clarify the role of pathway networks in the pituitary pathogenesis; and nitroproteomic data reveal the role of oxidative stress in signal pathways that are related to pituitary pathogenesis.
We realize a potential limitation of this study - a normal pituitary is an admixture of at least six pituitary cell types, whereas pituitary adenomas are generally an expanded clone of a single cell type, as described in our previous publication . This factor is a common problem with any human post-surgical tissue study. Enrichment of a single cell type of pituitary cells (such as with laser-capture microdissection, LCM) in our next in-depth investigation would be an effective method to resolve that potential limitation when the LCM-sensitivity problem is overcome for pituitary protein analysis.
Statistical consideration and biological significance
The objective of this study is to discover significant signal pathways or pathway networks from pituitary adenoma protein-mapping data, comparative proteomic data, and nitroproteomic data. The Fisher's exact test that is contained in the IPA program was used to uncover any statistically significant pathways or networks with a significance level of 0.05. For those four protein datasets in this study: we identified 37 significant canonical pathways and 6 pathway networks derived from our protein-mapping dataset, 9 significant canonical pathways and 3 pathway networks derived from our comparative proteomic dataset, 12 significant canonical pathways and 1 pathway network derived from our qualitative nitroproteomic dataset in adenomas, and 12 significant canonical pathways and 1 pathway network derived from our qualitative nitroproteomic dataset in controls.
No multiple-test correlation and significance level of 0.01 or 0.001 was used for this study based on two reasons: (1) a multiple-test correlation and significance level of 0.01 or 0.001 are more stringent criteria. Although those two parameters can reduce the probability of false positives, they also result in the loss of any biologically meaningful information. For example, if we use the significance level of 0.001 [or -log (0.001) = 3], then there will be 7 statistically significant canonical pathways (Figure 2) and 4 significant toxicological events (Figure 3) that derived from protein-mapping data; no significant canonical pathways (Figure 6) and no significant toxicological events (Figure 7) from comparative proteomics data; 1 significant canonical pathway (Figure 11) and 1 significant toxicological event (Figure 12) from adenoma nitroproteomic data; and 10 significant canonical pathways (Figure 14) from normal pituitary nitroproteomic data. In fact, many biologically significant DEPs (Additional file 1, Table S2) are derived from important pathways. Also, in Figure 11, more stringent criteria simply result in a significant canonical pathway - hepatic cholestasis; however, this pathway does not have much biologically meaning for pituitary adenomas. On the other hand, the canonical pathways p38 MAPK signaling, cell-cycle G2/M DNA damage-checkpoint regulation, and protein-ubiquitination pathways (Figure 11) were recognized as statistically significant with a significance level of 0.05, which can be reasonably linked to the real pituitary adenoma biological processes (described above). (2) Any statistical result is only a reference for biological significance. A statistically significant result must be reasonably interpreted with corresponding biological processes to decide its biological significance. Some statistically significant results would not have any real biological meaning. A typical example is that hemoglobin is often identified as statistically significant between tumor and control tissues; however, it cannot be concluded as biologically meaningful for a pituitary adenoma because its statistical significance probably derived from blood contamination. The canonical pathway hepatic cholestasis described above is another example. Moreover, for some cases, there might not be any statistical significance, but those proteins still have biological significance. For example, some genes have only a small change without any significant difference at the gene level; however, that small change at the gene level could lead to an amplified change on the protein level. As a biologist, this finding is still an interesting result. Therefore, when one uses a statistically significant pathway and network, one must carefully determine whether it is biologically relevant or whether the result really just occurs only by chance.
Based on those statistical considerations, those statistically significant pathways and networks that were generated from the Fisher's exact test with a significance level of 0.05 were reasonably explained within the pituitary adenoma biological system. Therefore, four important biological systems were discovered for pituitary adenomas, including mitochondrial dysfunction, oxidative stress, cell-cycle dysregulation, and the MAPK signaling abnormality. These four biological systems provide important clues and a clear direction for our next in-depth studies of pituitary adenomas.
This present study clarifies pathway networks that function in pituitary adenomas. The results demonstrate that mitochondria dysfunctions, oxidative stress, cell-cycle dysregulation, and the MAPK-signaling system are significantly associated with pituitary adenoma pathogenesis. Further experimental investigation is required to elucidate the biological consequences of those pathway networks and their relevance to the pathogenic mechanisms of pituitary adenoma. Those data could provide biomarkers, and could lead to the development of novel efficacious targets to treat pituitary adenomas.
Patients and tumor characterization
For protein-mapping analysis , the pituitary adenoma tissue (n = 1; from a black male 54-year-old) from the Memphis Regional Medical Center was used. During surgery, the tissue was removed, frozen immediately in liquid nitrogen, and stored (-80°C) until analysis.
For comparative proteomics analysis [2, 3], 15 pituitary tumors and 8 normal pituitary glands were used (Additional file 1, Table S5). Pituitary tumors (n = 15) were obtained from patients at the Emory University Hospital during transsphenoidal surgery. All tumors were microdissected and removed with a surgical microscope, rinsed in sterile saline, snap-frozen in liquid nitrogen, and stored (-80°C) until analysis. Each tumor fragment was confirmed independently by a neuropathologist as being homogenous and unadulterated by histology and immunohistochemistry prior to proteomics analysis. Eight control pituitary glands were obtained from the Memphis regional Medical Center (n = 7) and the National Disease Research Interchange (n = 1).
For nitroproteomics analysis [4–6], the clinically nonfunctional human pituitary adenoma tissue (n = 1)  and the normal pituitary post-mortem tissue (n = 1) [5, 6] were used. The pituitary adenoma tissue (n = 1; from a white male 39-year-old) was obtained from the University of Tennessee Baptist Hospital (Memphis, TN, USA); immunohistochemical studies showed that tumor cells were negative for the expression of FSH, LH, GH, PRL, TSH, or ACTH. During surgery, the tumor tissue was removed, frozen immediately in liquid nitrogen, and stored (-80°C) until analysis. The control pituitary tissue (n = 1; from a male 45-year-old, drowning) was obtained from the Memphis Regional Medical Center.
The experimental datasets that were analyzed in this study derived from our published human pituitary adenoma proteomic data: (i) a protein-mapping dataset that includes 111 proteins that were identified with two-dimensional gel electrophoresis (2DGE) and MS  (Additional file 1, Table S1), (ii) a comparative proteomic dataset that includes 56 DEP's that were identified with 2D gel-based comparative proteomics [2, 3] (Additional file 1, Table S2), (iii) a nitroproteomic dataset that includes nine nitroproteins, and three non-nitrated proteins that interacted with nitroproteins from a pituitary adenoma , that were identified with nitrotyrosine immunoaffinity enrichment and tandem mass spectrometry (MS/MS) (Additional file 1, Table S3), and eight nitroproteins from a pituitary control that were identified with 2DGE-based nitrotyrosine Western blots and MS/MS [5, 6] (Additional file 1, Table S4).
Ingenuity pathway analysis
The SwissProt accession number and gene name were used as the identifiers of each proteomic dataset. Each dataset was saved as an Excel file. Each proteomic dataset with identifier (.xls file) was input into the IPA analysis system http://www.ingenuity.com with the Core analysis platform. For the pituitary adenoma protein-mapping data and nitroprotein data, their Swiss-Prot accession numbers in the Excel format were input to the IPA data upload workflow. For the pituitary adenoma comparative proteomic data, the Swiss-Prot Accession numbers and the corresponding fold-change data in the Excel format were input to the IPA data upload workflow. The IPA system will automatically search the matched Gene/molecules, and will generate a two-dimensional table-style format to show which protein was mapped in the system for next-step analysis, and to show the unmapped proteins. The unmapped protein's Swiss-Prot accession number will be converted to the corresponding gene name by searching the ExPASy (Expert Protein Analysis System) proteomics server http://www.expasy.org. All Swiss-Prot accession numbers in combination with gene names were input to the IPA data upload workflow to generate the final mapped list for next-step analysis.
The dataset, including mapped IDs (protein and gene), was saved, and automatically generated five subdatasets, including the All IDs (= all input IDs), Unmapped IDs (without the matched molecules in the IPA system, unmapped IDs will not enter the next-step pathway analysis), Mapped IDs (match the corresponding molecules, and recognize the duplicate IDs), Network-eligible IDs (= Mapped IDs - Duplicated IDs), and Functions/Pathways/List-eligible IDs. For the duplicate IDs for the same protein/gene, the identifier with the highest fold-change was used in the pathway analysis; or, the first instance of the protein/gene was used in the pathway analysis in the absence of an expression value such as mapping proteomic data and nitroprotein data. Each subdataset contained ID, notes, molecules, description, location, type of biofunction, and drugs (Additional file 1, Table S1-S4); and the fold-change (Additional file 1, Table S2). The name of each molecule (gene; protein) appears in the pathway network nodes.
The Network-eligible IDs proceeded into the pathway network analysis by comparing the network-eligible molecules (genes; proteins) with the Ingenuity Pathways Analysis Knowledge Base (IPAKB). IPAKB is a curated database that contains (i) numerous scientific findings (n = ~2.2 million; February 13, 2009) that are extracted from hundreds of thousands of journal articles, textbooks, and other data sources, and (ii) many canonical pathways (n = 235; February 13, 2009) that are constructed from those scientific findings . The significance (p-values) of the association between the dataset and the canonical pathway was measured by comparing the number of use-specific proteins of interest that participate in a given pathway to the total number of occurrences of these genes in all pathway annotations that are stored in the IPAKB. A Fisher's exact test was used to calculate the p-value to determine the probability that the association between the genes in the dataset and the canonical pathway is explained only by chance. The level of statistical significance was set to p < 0.05. Each Pathway analysis generated the top networks, biofunctions/Tox functions, and top canonical pathways with a statistical significance (p < 0.05). A toxicity pathway is defined as a canonical pathway that is significantly associated with toxicity lists that are functional gene groupings based on critical biological processes and key toxicological responses; and those toxicity lists describe adaptive, defensive, or reparative responses to xenobiotic insult, and could be used to understand biological responses.
cyclin-dependent kinase inhibitor
differentially expressed proteins
two-dimensional gel electrophoresis
extracellular signal-regulated kinase
follicle-stimulating hormone, or follitropin
follicle-stimulating hormone-releasing hormone
Ingenuity Pathways Analysis
Ingenuity Pathways Analysis Knowledge Base
c-Jun N-terminal kinase
Kelch-like ECH-associated protein 1
luteinizing hormone, or lutropin
luteinizing hormone-releasing hormone
mitogen-activated protein kinase
tandem mass spectrometry
nuclear factor kappa B
nuclear factor E2-related factor-2
cyclic AMP-dependent kinase
pituitary tumor-transforming gene
raf kinase inhibitory protein
reactive nitrogen species
reactive oxygen species
thyrotropin-stimulating hormone, or thyrotropin.
The authors acknowledge the financial support from NIH (RR016679 to DMD), Shainberg Neuroscience Foundation (XZ), and William Webster Endowment Fund (XZ); and Ingenuity for the Ingenuity Pathway Analysis free-trial program, and the constructed canonical pathways.
- Zhan X, Desiderio DM: A reference map of a human pituitary adenoma proteome. Proteomics. 2003, 3 (5): 699-713. 10.1002/pmic.200300408.View ArticlePubMedGoogle Scholar
- Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM, Oyesiku NM: Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 2005, 65 (22): 10214-10222. 10.1158/0008-5472.CAN-05-0884.View ArticlePubMedGoogle Scholar
- Evans CO, Moreno CS, Zhan X, McCabe MT, Vertino PM, Desiderio DM, Oyesiku NM: Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary. 2008, 11 (3): 231-245. 10.1007/s11102-007-0082-2.View ArticlePubMedGoogle Scholar
- Zhan X, Desiderio DM: Nitroproteins from a human pituitary adenoma tissue discovered with a nitrotyrosine affinity column and tandem mass spectrometry. Anal Biochem. 2006, 354 (2): 279-289. 10.1016/j.ab.2006.05.024.View ArticlePubMedGoogle Scholar
- Zhan X, Desiderio DM: The human pituitary nitroproteome: detection of nitrotyrosylproteins with two-dimensional Western blotting, and amino acid sequence determination with mass spectrometry. Biochem Biophys Res Commun. 2004, 325 (4): 1180-1186. 10.1016/j.bbrc.2004.10.169.View ArticlePubMedGoogle Scholar
- Zhan X, Desiderio DM: Linear ion-trap mass spectrometric characterization of human pituitary nitrotyrosine-containing proteins. Int J Mass Spectrom. 2007, 259 (1-3): 96-104. 10.1016/j.ijms.2006.06.009.View ArticleGoogle Scholar
- Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, Walford GA, Sugiana C, Boneh A, Chen WK, Hill DE, Vidal M, Evans JG, Thorburn DR, Carr SA, Mootha VK: A mitochondrial protein compendium elucidates complex I disease biology. Cell. 2008, 134 (1): 112-123. 10.1016/j.cell.2008.06.016.View ArticlePubMedPubMed CentralGoogle Scholar
- Koene S, Smeitink J: Mitochondrial medicine: entering the era of treatment. J Intern Med. 2009, 265 (2): 193-209. 10.1111/j.1365-2796.2008.02058.x.View ArticlePubMedGoogle Scholar
- Modica-Napolitano JS, Singh KK: Mitochondria as targets for detection and treatment of cancer. Expert Rev Mol Med. 2002, 4 (9): 1-19. 10.1017/S1462399402004453.View ArticlePubMedGoogle Scholar
- Modica-Napolitano JS, Singh KK: Mitochondrial dysfunction in cancer. Mitochondrion. 2004, 4 (5-6): 755-762. 10.1016/j.mito.2004.07.027.View ArticlePubMedGoogle Scholar
- Schapira AH: Mitochondrial dysfunction in neurodegenerative diseases. Neurochem Res. 2008, 33 (12): 2502-2509. 10.1007/s11064-008-9855-x.View ArticlePubMedGoogle Scholar
- Ballinger SW: Mitochondrial dysfunction in cardiovascular disease. Free Radic Biol Med. 2005, 38 (10): 1278-1295. 10.1016/j.freeradbiomed.2005.02.014.View ArticlePubMedGoogle Scholar
- Anderson CM: Mitochondrial dysfunction in diabetes mellitus. Drug Dev Res. 1999, 46 (1): 67-79. 10.1002/(SICI)1098-2299(199901)46:1<67::AID-DDR10>3.0.CO;2-V.View ArticleGoogle Scholar
- Rabinovich RA, Bastos R, Ardite E, Llinas L, Orozco-Levi M, Gea J, Vilaro J, Barbera JA, Rodriguez-Roisin R, Fernandez-checa JC, Roca J: Mitochondrial dysfunction in COPD patients with low body mass index. Eur Respir J. 2007, 29 (4): 643-650. 10.1183/09031936.00086306.View ArticlePubMedGoogle Scholar
- Mabaliraja U, Dinda AK, Kumar S, Roshan R, Gupta P, Sharma SK, Ghosh B: Mitochondrial structural changes and dysfunction are associated with experimental allergic asthma. J Immunol. 2008, 181 (5): 3540-3548.View ArticleGoogle Scholar
- Kroemer G: Mitochondria in cancer. Oncogene. 2006, 25 (34): 4630-4632. 10.1038/sj.onc.1209589.View ArticlePubMedGoogle Scholar
- Halabe Bucay A: The biological significance of cancer: Mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment. Med Hypotheses. 2007, 69 (4): 826-828. 10.1016/j.mehy.2007.02.002.View ArticlePubMedGoogle Scholar
- Goebel HH, Schulz F, Rama B: Ultrastructurally abnormal mitochondria in the pituitary oncocytoma. Acta Neurochir. 1980, 51 (3-4): 195-201. 10.1007/BF01406745.View ArticlePubMedGoogle Scholar
- Horoupian DS: Large mitochondria in a pituitary adenoma with hyperprolactinemia. Cancer. 1980, 46 (3): 537-542. 10.1002/1097-0142(19800801)46:3<537::AID-CNCR2820460319>3.0.CO;2-6.View ArticlePubMedGoogle Scholar
- Niroi N, Chrousos GP, Kohn B, Lafferty A, Abu-Asab M, Bonat S, White A, Bornstein SR: Adrenocortical-pitutiary hybrid tumor causing Cushing's syndrome. J Clin Endocrinol Metab. 2001, 86 (6): 2631-2637. 10.1210/jc.86.6.2631.Google Scholar
- Yang QH, Xu JN, Xu RK, Pang SF: Inhibitory effects of melatonin on the growth of pituitary prolactin-secreting tumor in rats. J Pineal Res. 2006, 40 (3): 230-235. 10.1111/j.1600-079X.2005.00305.x.View ArticlePubMedGoogle Scholar
- Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S: Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. Eur J Endocrinol. 2007, 156 (2): 203-216. 10.1530/eje.1.02326.View ArticlePubMedGoogle Scholar
- Roncaroli F, Scheithauer BW, Cenacchi G, Horvath E, Kovacs K, Lloyd RV, Abell-Aleff P, Santi M, Yates AJ: 'Spindle cell oncotytoma' of the adenohypophysis: a tumor of folliculostellate cells?. Am J Surg Pathol. 2002, 26: 1048-1055. 10.1097/00000478-200208000-00010.View ArticlePubMedGoogle Scholar
- John AP: Dysfunctional mitochondria, not oxygen insufficiency, cause cancer cells to produce inordinate amounts of lactic acid: the impact of this on the treatment of cancer. Med Hypotheses. 2001, 57 (4): 429-431. 10.1054/mehy.2001.1335.View ArticlePubMedGoogle Scholar
- Kluza J, Gallego MA, Loyens A, Beauvillain JC, Sousa-Faro JMF, Cuevas C, Marchetti P, Bailly C: Cancer cell mitochondria are direct proapoptotic targests for the marine antitumor drug lamellarin D. Cancer Res. 2006, 66 (6): 3177-3187. 10.1158/0008-5472.CAN-05-1929.View ArticlePubMedGoogle Scholar
- Garber K: Targeting mitochondria emerges as therapeutic strategy. J Natl Cancer Inst. 2005, 97 (24): 1800-1801. 10.1093/jnci/dji455.View ArticlePubMedGoogle Scholar
- Galluzzi L, Larochette N, Zamzami N, Kroemer G: Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene. 2006, 25 (34): 4812-4830. 10.1038/sj.onc.1209598.View ArticlePubMedGoogle Scholar
- Modica-Napolitano JS, Kulawiec M, Singh KK: Mitochondria and human cancer. Cur Mol Med. 2007, 7 (1): 121-131. 10.2174/156652407779940495.View ArticleGoogle Scholar
- Bell EL, Klimova T, Chandel NS: Targeting the mitochondria for cancer therapy: regulation of hypoxia-inducible factor by mitochondria. Antioxid Redox Signal. 2008, 10 (3): 635-640. 10.1089/ars.2007.1655.View ArticlePubMedGoogle Scholar
- Tandon VR, Sharma S, Mahajan A, Bardi GH: Oxidative stress: A novel strategy in cancer treatment. J K Science. 2005, 7 (1): 1-3.Google Scholar
- Toyokuni S: Molecular mechanisms of oxidative stress-induced carcinogenesis: from epidemiology to oxygenomics. IUBMB Life. 2008, 60 (7): 441-447. 10.1002/iub.61.View ArticlePubMedGoogle Scholar
- Halliwell B: Oxidative stress and cancer: have we moved forward?. Biochem J. 2007, 401 (1): 1-11. 10.1042/BJ20061131.View ArticlePubMedGoogle Scholar
- Ceccatelli S, Hulting AL, Zhang X, Gustafsson L, Villar M, Hokfelt T: Nitric oxide synthase in the rat anterior pituitary gland and the role of nitric oxide in regulation of LH secretion. Proc Natl Acad Sci USA. 1993, 90 (23): 11292-11296. 10.1073/pnas.90.23.11292.View ArticlePubMedPubMed CentralGoogle Scholar
- Ueta Y, Levy A, Powell MP, Lightaman SL, Kinoshita Y, Yokota A, Shibuya I, Yamashita H: Neuronal nitric oxide synthase gene expression in human pituitary tumours: a possible association with somatotroph adenomas and growth hormone-releasing hormone gene expression. Clin Endocrinol (Oxf). 1998, 49 (1): 29-38. 10.1046/j.1365-2265.1998.00399.x.View ArticleGoogle Scholar
- Lloyd RV, Jin L, Qian X, Zhang S, Scheithauer BW: Nitric oxide synthase in the human pituitary gland. Am J Pathol. 1995, 146 (1): 86-94.PubMedPubMed CentralGoogle Scholar
- Pawlikowshi M, Winczyk K, Jaranowska M: Immunohistochemical demonstration of nitric oxide synthase (NOS) in the normal rat pituitary gland, estrogen-induced rat pituitary tumor and human pituitary adenomas. Folia Histochem Cytobiol. 2003, 41 (2): 87-90.Google Scholar
- Kruse A, Broholm H, Rubin I, Schmidt K, Lauritzen M: Nitric oxide synthase activity in human pituitary adenomas. Acta Neurol Scand. 2002, 106 (6): 361-366. 10.1034/j.1600-0404.2002.01138.x.View ArticlePubMedGoogle Scholar
- Vankelecom H, Matthys P, Denef C: Inducible nitric oxide synthase in the anterior pituitary gland: induction by interferon-r in a subpopulation of folliculostellate cells and in an unidentifiable population of nonhormone-secreting cells. J Histochem Cytochem. 1997, 45 (6): 847-857.View ArticlePubMedGoogle Scholar
- Riedel W: Role of nitric oxide in the control of the hypothalamic-pituitary-adrenocortical axis. Z Rheumatol. 2002, 59 (suppl 2): II-36-II-42.Google Scholar
- McCann SM, Haens G, Mastronardi C, Walczewska A, Karanth S, Rettori V, Yu WH: The role of nitric oxide (NO) in control of LHRH release that mediates gonadotropin release and sexual behavior. Curr Pharm Des. 2003, 9 (5): 381-390. 10.2174/1381612033391766.View ArticlePubMedGoogle Scholar
- McCann SM, Karanth S, Mastronardi CA, Dees WL, Childs G, Miller B, Sower S, Yu WH: Control of gonadotropin secretion by follicle-stimulating hormone-releasing factor, luteinizing hormone-releasing hormone, and leptin. Arch Med Res. 2001, 32 (6): 476-485. 10.1016/S0188-4409(01)00343-5.View ArticlePubMedGoogle Scholar
- Pinilla L, Gonzalez LC, Tena-Sempere M, Bellido C, Aguilar E: Effects of systemic blockade of nitric oxide synthases on pulsatile LH, prolactin, and GH secretion in adult male rats. Horm Res. 2001, 55 (5): 229-235. 10.1159/000050001.View ArticlePubMedGoogle Scholar
- Duvilanski BH, Zambruno C, Seilicovich A, Pisera D, Lasaga M, Diaz MC, Belova N, Rettori V, McCann SM: Role of nitric oxide in control of prolactin release by the adenohypophysis. Proc Natl Acad Sci USA. 1995, 92 (1): 170-174. 10.1073/pnas.92.1.170.View ArticlePubMedPubMed CentralGoogle Scholar
- Pinilla L, Tena-Sempere M, Aguilar E: Nitric oxide stimulates growth hormone secretion in vitro through a calcium- and cyclic guanosine monophosphate-independent mechanism. Horm Res. 1999, 51 (5): 242-247. 10.1159/000023378.View ArticlePubMedGoogle Scholar
- Cuttica CM, Giusti M, Bocca L, Sessarego P, De Martini D, Valenti S, Spaziante R, Giordano G: Nitric oxide modulates in vivo and in vitro growth hormone release in acromegaly. Neuroendocrinology. 1997, 66 (6): 426-431. 10.1159/000127268.View ArticlePubMedGoogle Scholar
- Bocca L, Valenti S, Cuttica CM, Spaziante R, Giordano G, Giusti M: Nitric oxide biphasically modulates GH secretion in cultured cells of GH-secreting human pituitary adenomas. Minerva Endocrinol. 2000, 25 (3-4): 55-59.PubMedGoogle Scholar
- Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006, 160 (1): 1-40. 10.1016/j.cbi.2005.12.009.View ArticlePubMedGoogle Scholar
- Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH, Wallace DC, Epstein CJ: Dilated cardiomyopathy and neonatal lethality in mutant mice lacking mangese superoxide dismutase. Nat Genet. 1995, 11 (4): 376-381. 10.1038/ng1295-376.View ArticlePubMedGoogle Scholar
- Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson RL, Van Remmen H, Epstein CJ, Huang TT: CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene. 2005, 24 (3): 367-380. 10.1038/sj.onc.1208207.View ArticlePubMedGoogle Scholar
- Melov S, Doctrow SR, Schneider JA, Haberson J, Patel M, Coskun PE, Huffman K, Wallace DC, Malfroy B: Lifepan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutasecatalase mimetics. J Neurosci. 2001, 21 (21): 8348-8353.PubMedGoogle Scholar
- Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH: 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med. 2005, 11 (12): 571-578. 10.1016/j.molmed.2005.10.006.View ArticlePubMedGoogle Scholar
- Chu FF, Esworthy RS, Chu PG, Longmate JA, Huycke MM, Wilczynski S, Doroshow JH: Bacteria-induced intestinal cancer in mice with disrupted GPx1 and Gpx2 genes. Cancer Res. 2004, 64 (3): 962-968. 10.1158/0008-5472.CAN-03-2272.View ArticlePubMedGoogle Scholar
- Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH, Van Etten RA: Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003, 424 (6948): 561-565. 10.1038/nature01819.View ArticlePubMedGoogle Scholar
- Kurisaka M, Nakajo T, Mori K: Immunohistochemical study on the expression of copper and zinc-superoxide dismutase (Cu, Zn-SOD) in human adenohypophysis and pituitary adenomas. No To Shinkei. 2004, 46 (10): 948-954.Google Scholar
- Li W, Kong AN: Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog. 2009, 48 (2): 91-104. 10.1002/mc.20465.View ArticlePubMedPubMed CentralGoogle Scholar
- Osburn WO, Wakabayashi N, Misra V, Nilles T, Biswal S, Trush MA, Kensler TW: Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of superoxide anion. Arch Biochem Biophys. 2006, 454 (1): 7-15. 10.1016/j.abb.2006.08.005.View ArticlePubMedPubMed CentralGoogle Scholar
- Pi J, Zhang Q, Woods CG, Wong V, Collins S, Anderson ME: Activation of Nrf2-mediated oxidative stress response in macrophages by hypochlorous acid. Toxicol Appl Pharmacol. 2008, 226 (3): 236-243. 10.1016/j.taap.2007.09.016.View ArticlePubMedGoogle Scholar
- Dhakshinamoorthy S, Porter AG: Nitric oxide-induced transcriptional up-regulation of protective genes by Nrf2 via the antioxidant response element counteracts apoptosis of neuroblastoma cells. J Biol Chem. 2004, 279 (19): 20096-20107. 10.1074/jbc.M312492200.View ArticlePubMedGoogle Scholar
- Mann GE, Rowlands DJ, Li FYL, de Winter P, Siow RCM: Activation of endothelial nitric oxide synthase by dietary isoflavones: Role of NO in Nrf2-mediated antioxidant gene expression. Cardiovasc Res. 2007, 75 (2): 261-274. 10.1016/j.cardiores.2007.04.004.View ArticlePubMedGoogle Scholar
- Dinkova-Kostova AT, Holtzclaw WD, Kensler TW: The role of Keap1 in cellular protective responses. Chem Res Toxicol. 2005, 18 (12): 1779-1791. 10.1021/tx050217c.View ArticlePubMedGoogle Scholar
- Yates MS, Kensler TW: Chemopreventive promise of targeting the Nrf2 pathway. Drug News Perspect. 2007, 20 (2): 109-117. 10.1358/dnp.2007.20.2.1083437.View ArticlePubMedGoogle Scholar
- Lim JH, Kim KM, Kim SW, Hwang O, Choi HJ: Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: Novel cytoprotective mechanism against oxidative damage. Pharmacol Res. 2008, 57 (5): 325-331. 10.1016/j.phrs.2008.03.004.View ArticlePubMedGoogle Scholar
- Turner HE, Nagy ZS, Nullivan N, Esiri MM, Wass JAH: Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin Endocrinol. 2000, 53 (3): 337-344. 10.1046/j.1365-2265.2000.01088.x.View ArticleGoogle Scholar
- Musat M, Vax VV, Borboli N, Gueorguiev M, Bonner S, Korbonits M, Grossman AB: Cell cycle dysregulation in pituitary oncogenesis. Front Horm Res. 2004, 32: 34-62. full_text.View ArticlePubMedGoogle Scholar
- Yu R, Ren SG, Horwitz GA, Wang Z, Melmed S: Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol. 2000, 14 (8): 1137-1146. 10.1210/me.14.8.1137.View ArticlePubMedGoogle Scholar
- Saeger W: Proliferation markers and cell cycle inhibitors in pituitary adenomas. Front Horm Res. 2004, 32: 110-126. full_text.View ArticlePubMedGoogle Scholar
- Heaney AP: Pituitary tumour pathogenesis. Br Med Bull. 2006, 75-76: 81-97. 10.1093/bmb/ldh062.View ArticlePubMedGoogle Scholar
- Farrell WE, Clayton RN: Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol. 2000, 21 (3): 174-198. 10.1006/frne.1999.0195.View ArticlePubMedGoogle Scholar
- Yu R, Ren SG, Melmed S: Proteasome inhibitors induce apoptosis in growth hormone- and prolactin-secreting rat pituitary tumor cells. J Endocrinol. 2002, 174 (3): 379-386. 10.1677/joe.0.1740379.View ArticlePubMedGoogle Scholar
- Dhillon AS, Hagan S, Rath O, Kolch W: MAP kinase signaling pathways in cancer. Oncogene. 2007, 26 (22): 3279-3290. 10.1038/sj.onc.1210421.View ArticlePubMedGoogle Scholar
- Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, Bastian BC, Springer C, Marais R: In melanoma, Ras mutations are accompanied by switching signaling from BRAF to CRAF and discrupted cyclin AMP signaling. Cancer Res. 2006, 66 (19): 9483-9491. 10.1158/0008-5472.CAN-05-4227.View ArticlePubMedGoogle Scholar
- Bubici C, Papa S, Pham CG, Zazzeroni F, Franzoso G: NF-kappa B and JNK: an intricate affair. Cell Cycle. 2004, 3 (12): 1524-1529.View ArticlePubMedGoogle Scholar
- Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell. 2000, 103 (2): 239-252. 10.1016/S0092-8674(00)00116-1.View ArticlePubMedGoogle Scholar
- Bulavin DV, Fornace AJ: p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res. 2004, 92: 95-118. full_text.View ArticlePubMedGoogle Scholar
- Wada T, Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004, 23 (16): 2838-2849. 10.1038/sj.onc.1207556.View ArticlePubMedGoogle Scholar
- Johnson GL, Lpadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002, 298 (5600): 1911-1912. 10.1126/science.1072682.View ArticlePubMedGoogle Scholar
- English JM, Cobb MH: Pharmcological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002, 23 (1): 40-45. 10.1016/S0165-6147(00)01865-4.View ArticlePubMedGoogle Scholar
- Olson JM, Hallahan AR: p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med. 2004, 10 (3): 125-129. 10.1016/j.molmed.2004.01.007.View ArticlePubMedGoogle Scholar
- Vallar L, Spada A, Giannattasio G: Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature. 1987, 330 (6148): 566-568. 10.1038/330566a0.View ArticlePubMedGoogle Scholar
- Willamson EA, Daniels M, Foster S, Kelly WF, Kendall-Taylor P, Harris PE: Gsα and Gi2α mutations in clinically nonfunctioning pituitary tumors. Clin Endocrinol (Oxf). 1994, 41 (5): 815-820. 10.1111/j.1365-2265.1994.tb02798.x.View ArticleGoogle Scholar
- Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jamesom LJ: Ras mutations in human pituitary tumors. J Clin Endocrinol Metab. 1992, 74 (4): 914-919. 10.1210/jc.74.4.914.View ArticlePubMedGoogle Scholar
- Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V, Garcia E, Czirjak S, Hanzely Z, Kola B, Korbonits M, Grossman AB: A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf). 2007, 66 (3): 348-352. 10.1111/j.1365-2265.2006.02735.x.View ArticleGoogle Scholar
- Fougner SL, Bollerslev J, Latif F, Hald JK, Lund T, Ramm-Pettersen J, Berg JP: Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J Clin Endocrinol Metab. 2008, 93 (4): 1211-1216. 10.1210/jc.2007-2272.View ArticlePubMedGoogle Scholar
- Hubina E, Ruscica M, Nanzer AM, Czirjak S, Goth MI, Grossman AB, Korbonits M: Novel molecular aspects of pituitary adenomas. J Endocrinol Invest. 2005, 28 (11 Suppl International): 87-92.PubMedGoogle Scholar
- An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JH: Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol. 2003, 206 (1-2): 49-62. 10.1016/S0303-7207(03)00236-3.View ArticlePubMedGoogle Scholar
- Zhan X, Desiderio DM: Comparative proteomics analysis of human pituitary adenomas: current status and future perspectives. Mass Spectrom Rev. 2005, 24 (6): 783-813. 10.1002/mas.20039.View ArticlePubMedGoogle Scholar
- Bordignon J, Probst CM, Mosimann ALP, Pavoni DP, Stella V, Buck GA, Satproedprai N, Fawcett P, Zanata SM, de Noronha L, Krieger MA: Expression profile of interferon stimulated genes in central nervous system of mice infected with dengue virus type-1. Virology. 2008, 377 (2): 319-329. 10.1016/j.virol.2008.04.033.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1755-8794/3/13/prepub